Диссертация (Анализ применения фармакогенетического тестирования для индивидуализации применения пероральных антикоагулянтов и статинов у пациентов терапевтического профиля в условиях функционирования центра персонализированной медицины), страница 27

Systematic overview of warfarinand its drug and food interactions. Arch. Intern. Med. 2005; 165: 1095-110689.Holder K. Myalgias and Myopathies: Drug-Induced Myalgias and Myopathies. FPEssent. 2016; 440:23-790.Hou Q. et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case–control studies. Medicine. 2015; 94(37):1-991.Hsu J. C. et al. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV diseaseseverity //Journal of the American College of Cardiology. – 2013; 61(22):2288-2295.92.Hughes M., et al. Stroke and thromboembolism in atrial fibrillation: a systematicreview of stroke risk stratification schema and cost effectiveness data // Thrombosis andHaemostasis.

2008; 99:.295-304.93.Insull W., Ghali J.K., Hassman D.R. SOLAR Study Group Achieving low densitylipoprotein cholesterol goals in high risk patients in managed care: comparison ofrosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007;82:543—550.94.J.H. Jansson, T.K. Nilsson, O. Johnson Von Willebrand factor, tissue plasminogenactivator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 yearfollow up of survivors of acute myocardial infarction.

Heart, 1998; 80: 334–337.95.James H Chesebro, MD, Valentin Fuster, MD, Lila R Elveback, PhD, ,et al.Adherence with statin therapy in elderly patients with and without acute coronarysyndromes. JAMA 2002; 288:462-467.96.Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical PharmacogeneticsImplementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarindosing. Clin Pharmacol Ther 2011 ;90(4):625-9.97.Johnston S.

C. et al. National Stroke Association guidelines for the management oftransient ischemic attacks. Annals of neurology. 2006; 3(60):301-313.13898.Jula A, Marniemi J, Huupponen R, et al. Effects of diet and simvastatin on serumlipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.JAMA 2002; 287:598-60599.Kalyanam S., Syed M., Mihai G., Antithrombotic therapy in atrial fibrillation: Areview of randomized trials with special reference to the stroke prevention in atrialfibrillation II (SPAF II) trial.

Elsevier. 1996; 4(38):337–342100. Kamel H., Johnston S.C., Easton J.D. et al. Cost-Effectiveness of DabigatranCompared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and PriorStroke or Transient Ischemic Attack. Stroke. 2012101. Karen A. et al. Therapeutic use of warfarin and other vitamin K antagonists[Электронный ресурс].

– 2013.102. Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulationwith extended anticoagulation for a first episode of idiopathic venous thromboembolism.New England Journal of Medicine. 1999;340: 901–903.103. Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patientswith advanced gastric adenocarcinoma.

Invest New Drugs 2001; 19:81-3.104. Kimmel S. E. et al. The influence of patient adherence on anticoagulation control withwarfarin: results from the International Normalized Ratio Adherence and Genetics (INRANGE) Study //Archives of Internal Medicine. 2007; 3(167):229-235.105. Kirchhof P., Auricchio А., Bax J. et al. Outcome parameters for trials in atrialfibrillation: executive summary. Recommendations from a consensus conference organizedby the German Atrial Fibrillation Competence NETwork (AFNET) and the European HeartRhythm Association (EHRA). Eur. Heart J.

2007; 28:2803-2817.106. Klein M, Mann H, Plestilova L, et al. Increasing incidence of immune-mediatednecrotizing myopathy: single-centre experience. Rheumatology. 2015;54(11):2010– 2014.107. Krajčíová, Ľubica, et al. "Frequency of selected single nucleotide polymorphismsinfluencing the warfarin pharmacogenetics in Slovak population." European journal ofhaematology 93.4 (2014): 320-328.139108. Kukes I.V., Sychev D.A.. Analysis of frequency and structure of adverse reactionsfrom oral anticoagulants, recorded by spontaneous reporting in Russia.

J Basic and ClinicalPharmacology 2011; 109 (Suppl. 1): 76.109. L.A. Donnelly, A.S. Doney, R. Tavendale, C.C. Lang, E.R. Peason, H.M. Colhoun,M.I. McCarthy, A.T. Hattersley, A.D. Morris, C.N. Palmer, Common nonsynonymoussubstitutions in SLCO1B1 predispose to statin intolerance in routinely treated individualswith type 2 diabetes: a go-DARTS study, Clin. Pharmacol.

Ther. 2011; 89:210-216.110. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment onnatural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinonein skeletal muscle. Am J Cardiol 1996; 77:851-4.111. Lafuente-Lafuente C. et al. Antiarrhythmics for maintaining sinus rhythm aftercardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007; 4.112. Laurence D.R. Clinical Pharmacology. — Edinburgh, London and New York:Churchill Livingstone, 1973; 234–235113. Lee B.H., et al. The effect and safety of the Antithrombotic therapies in patients withatrial fibrillation and CHADS2 score 1.

J Cardiovasc Electrophysiol, 2010; in press.114. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 CYP2C9 polymorphisms: acomprehensive review of the in-vitro and human data // Pharmacogenetics. 2002; 12: 251263.115. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency – a novel mechanismof statin-induced myalgia? Clinical Endocrinology (Oxford) 2009; 71:154-5116. Leuschen J, Mortensen E.M., Frei C.R., et al.

Association of statin use with cataracts:a propensity score-matched analysis. .JAMA Ophthalmol. 2013 Nov;131(11):1427-34.117. Leusink M. et al. Seventeen years of statin pharmacogenetics: a systematic review//Pharmacogenomics. 2016; 2(17):163-180118. Levine M., Raskob G., Landefeld C. S., Kearon C. Hemorrhagic complications ofanticoagulant treatment. Chest 1998; 114: 511—523.119. Lévy, Samuel, et al. "Characterization of different subsets of atrial fibrillation ingeneral practice in France." Circulation 99.23 (1999): 3028-3035.140120.

Li J. H. et al. Genetically guided statin therapy on statin perceptions, adherence, andcholesterol lowering: a pilot implementation study in primary care patients Journal ofpersonalized medicine. 2014. 2(4):147-162121.Li T., et al. "Identification of the gene for vitamin K epoxide reductase." Nature427.6974 (2004): 541-544.122.Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, et al.Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across3 racial groups.

Blood. 2010;115(18):3827–34.123. Lin H.J., Wolf P.A., Kelly_Hayes M., et al. Stroke severity in atrial fibrilla_ tion: theFramingham study. Stroke 1996; 27: 1760-1764.124. Linde R., Peng L., Desai M., Feldman D. The role of vitamin D and SLCO1B1*5gene polymorphism in statin-associated myalgias. Dermatoendocrinology. 2010; 2 (2): 77–84125. Lindh J.D., Holm L., Andersson M.L., Rane A. Influence of CYP2C9 genotype onwarfarin dose requirements - a systematic review and meta-analysis. Eur J ClinPharmacol2009;65(4):365-75.126.

Link E, Parish S, Armitage J, et al. SEARCH Collaborative Group. SLCO1B1variants and statin-induced myopathy a genomewide study. The New England Journal ofMedicine. 2008;359(8): 789-799.127. Lip GY (February 2011). «Implications of the CHA(2)DS(2)-VASc and HAS-BLEDScores for thromboprophylaxis in atrial fibrillation». Am. J. Med. 124 (2): 111–4128. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006; 92:4-8129. Lloyd-Jones D, Adams R, Carnethon M, et al.

(January 2009). «Heart disease andstroke statistics--2009 update: a report from the American Heart Association StatisticsCommittee and Stroke Statistics Subcommittee». Circulation 119(3): 480–86130. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al.Interindividual variability in sensitivity to warfarin–Nature or nurture? Clin PharmacolTher.

2001;70(2):159–64.131. Low P, Andersson M, Edlund C, Dallner G. Effects of mevinolin treatment on tissuedolichol and ubiquinone levels in the rat. Biochim Biophys Acta 1992; 1165:102-9.141132. Lubitz S.A., Rosen A.B., Ellinor P.T. et al.

Stroke risk in AF: do AF patterns matter?Eur. Heart J. 2010; Vol.31:908-910.133. Marcoff, L., & Thompson, P. D. The role of coenzyme Q10 in statin-associatedmyopathy: a systematic review. Journal of the American College of Cardiology, 2007;23(49):2231-2237.134. Mant J., Hobbs R., Fletcher K. et al. Warfarin versus aspirin for stroke prevention inan elderly community population with atrial fibrillation (the Birmingham AtrialFibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial.Lancet -2007; 370: 493–503135.

Marciante, Kristin D., et al. "Cerivastatin, genetic variants, and the risk ofrhabdomyolysis." Pharmacogenetics and genomics 2011; 5(21):280-288136. Marini C., De Santis F., Sacco S., et al. Contribution of atrial fibrillation to incidenceand outcome of ischemic stroke: results from a population_based study. Stroke 2005; 36:1115-1159.137. McDonald H.